2021
Chapter 48 Malignancies in systemic lupus erythematosus
Ladouceur A, Tissera H, Clarke A, Ramsey-Goldman R, Gordon C, Hansen J, Bernatsky S. Chapter 48 Malignancies in systemic lupus erythematosus. 2021, 461-467. DOI: 10.1016/b978-0-12-814551-7.00048-9.ChaptersSystemic lupus erythematosusSLE patientsLupus erythematosusGeneral populationOverall cancer incidence ratesHormone-sensitive cancersCancer incidence ratesRisk of breastDrug exposureIncidence rateProstate cancerHormonal changesHigh riskCancer profilePatientsCancerGenetic factorsErythematosusRiskPotential reasonsLymphomaMalignancyPathophysiologyPopulationBreast
2016
Breast cancer in systemic lupus
Bernatsky S, Ramsey-Goldman R, Petri M, Urowitz MB, Gladman DD, Fortin P, Ginzler E, Romero-Diaz J, Peschken C, Jacobsen S, Hanly JG, Gordon C, Nived O, Yelin EH, Isenberg D, Rahman A, Bae SC, Joseph L, Witte T, Ruiz-Irastorza G, Aranow C, Kamen D, Sturfeldt G, Foulkes WD, Hansen JE, St Pierre Y, Raymer PC, Tessier-Cloutier B, Clarke AE. Breast cancer in systemic lupus. Lupus 2016, 26: 311-315. PMID: 27687028, PMCID: PMC5250552, DOI: 10.1177/0961203316664595.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusBreast cancer riskAnti-dsDNA positivityBreast cancer casesBreast cancerCancer riskDisease activitySLE patientsHazard ratioCancer casesSLE samplesBreast cancer hazard ratioCancer hazard ratioCumulative disease activityFemale SLE patientsCase-cohort analysisCancer-free controlsCohort entrySLE durationClinical characteristicsSystemic lupusClinical factorsLupus erythematosusDrug exposureFamily historyChapter 46 Malignancies in Systemic Lupus Erythematosus
Tissera H, Clarke A, Goldman R, Gordon C, Hansen J, Bernatsky S. Chapter 46 Malignancies in Systemic Lupus Erythematosus. 2016, 411-415. DOI: 10.1016/b978-0-12-801917-7.00046-2.ChaptersSystemic lupus erythematosusSLE patientsGeneral populationLupus erythematosusOverall cancer incidence ratesHormone-sensitive cancersCancer incidence ratesRisk of breastDrug exposureIncidence rateProstate cancerHormonal changesHigh riskCancer profilePatientsCancerGenetic factorsErythematosusRiskPopulationPotential reasonsLymphomaMalignancyPathophysiologyBreast
2012
Targeting Cancer with a Lupus Autoantibody
Hansen JE, Chan G, Liu Y, Hegan DC, Dalal S, Dray E, Kwon Y, Xu Y, Xu X, Peterson-Roth E, Geiger E, Liu Y, Gera J, Sweasy JB, Sung P, Rockwell S, Nishimura RN, Weisbart RH, Glazer PM. Targeting Cancer with a Lupus Autoantibody. Science Translational Medicine 2012, 4: 157ra142. PMID: 23100628, PMCID: PMC3713477, DOI: 10.1126/scitranslmed.3004385.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusAnti-DNA antibodiesLupus autoantibodiesProstate cancerCancer therapyLupus anti-DNA antibodiesHuman tumor xenograftsDNA-damaging therapiesCultured tumor cellsSLE patientsLupus erythematosusSLE pathophysiologyAutoimmune diseasesDose doxorubicinTumor xenograftsAutoantibodiesHuman cancer cellsTherapyTherapeutic agentsTumor cellsCancerCancer cellsLupusMalignancyPrecise role